Drug Trial Radar · NCT02864381
Study to Evaluate the Efficacy and Safety of Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma
Last checked: Nov 20, 2026Latest source record: Sep 18, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
144
Actual
Start
Sep 1, 2016
Primary completion
Nov 8, 2017
Study completion Aug 23, 2019
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Aug 12, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate and compare the efficacy of andecaliximab (GS-5745) in combination with nivolumab versus nivolumab alone in adults with recurrent gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Conditions
- Gastric Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
Interventions
AndecaliximabDrug
800 mg administered via IV infusion
NivolumabDrug
3 mg/kg administered via IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR)Time frame: Up to 41 weeks
Locations
34 sites in 9 countries. Site status is shown where the registry gives one.
Site not named
Los Angeles, California
Site not named
San Francisco, California
Site not named
Chicago, Illinois
Site not named
Fort Wayne, Indiana
Site not named
St Louis, Missouri
Site not named
New York, New York
Site not named
Albury, New South Wales, Australia
Site not named
Wahroonga, New South Wales, Australia
Site not named
Douglas, Queensland, Australia
Site not named
Hobart, Tasmania, Australia
Site not named
La Louvière, Hainaut, Belgium
Site not named
Ghent, Oost-Vlaanderen, Belgium
Site not named
Leuven, Vlaams Brabant, Belgium
Site not named
Brest, Finistère, France
Site not named
Reims, Marne, France
Site not named
Villejuif, Val-de-Marne, France
Site not named
Budapest, Hungary
Site not named
Debrecen, Hungary
Site not named
Meldola, Forli-Cesena, Italy
Site not named
Genova, Ligura, Italy
Site not named
Milan, Lombardy, Italy
Site not named
Pisa, Tuscany, Italy
Site not named
Poznan, Poland
Site not named
Warsaw, Poland
Site not named
Brzozów, Podkarpackie Voivodeship, Poland
Site not named
Barcelona, Spain
Site not named
Barcelona, Barcelona, Spain
Site not named
Majadahonda, Madrid, Spain
Site not named
Bristol, United Kingdom
Site not named
Edgbaston, United Kingdom
Site not named
London, United Kingdom
Site not named
London, United Kingdom
Site not named
Manchester, United Kingdom
Site not named
Sutton, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.